Clinical study assessing antibody adding (panitumumab) to a chemotherapy of reference in metastatic colorectal cancer (FOLFOX), following a strategy with a switch between full treatment and light treatment.

ABSTRACT: Primary objectives: The primary objective is to evaluate the disease control duration Primary endpoints: the primary endpoint is the disease control duration

DISEASE(S): Adénocarcinome Colorectal Métastatique Sans Mutation Ras,Metastatic Colorectal Adenocarcinoma Without A Ras Mutation

PROVIDER: 2536894 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR